To view more news and media here in our Newsroom

Click Here

Continence Confidence: Prostatectomy Patients Reporting ‘Startling’ Success After Robotic Retzius-Sparing Surgery

For healthcare industry executive Sean Hawkins, prostate cancer runs in the family. After his own diagnosis last year, the then 49-year-old already knew the potential challenges of treatment -- including losing control of his bladder. However, a breakthrough method of prostate surgery known as Retzius-sparing is now eliminating continence issues for many men treated at MedStar Georgetown University Hospital. “You go through all sorts of mental gymnastics when you’re confronted with cancer,” he says. “My main concern was the ability to get back to normal.” After consulting with MedStar Georgetown urological surgeon Keith Kowalczyk, MD, Hawkins learned that he was…

Read More

Personalized Medicine Clinical Trial Underway for Type of Incontinence Common in Women

WASHINGTON D.C. – A novel clinical trial aims to study a treatment for a common problem among older women––accidental urine leakage––by using a patient’s own muscle cells. The study, now underway in the Washington area, is for women with stress urinary incontinence that has not been addressed by conservative treatment such as behavior modifications and pelvic-floor muscle exercises. Stress urinary incontinence, or SUI, often occurs when the tissues that support the bladder and/or the muscles that regulate the release of urine weaken, and can have a negative impact on a woman’s quality of life. The condition is especially common after…

Read More

Georgetown-Led Study Leads to First FDA-Approved Drug in Decades to Improve Survival in Small Cell Lung Cancer

The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriq®, Genentech) in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for people with the deadly disease. “This is monumental for lung cancer patients,” says Stephen Liu, MD, an oncologist at MedStar Georgetown University Hospital who specializes in treating lung cancer and co-led the clinical trial leading to today’s approval through the Georgetown Lombardi Comprehensive Cancer Center. “Atezolizumab allowed us to achieve what for we thought for decades was beyond reach: an improvement in…

Read More

Researchers Decode How Cancer Drug Works in Brains of Parkinson’s Disease Patients

WASHINGTON  — Laboratory analysis from the first arm of a phase II clinical trial testing the use of nilotinib in patients with Parkinson’s disease demonstrates precisely how the agent increases levels of dopamine in the brains of study participants, says a research team at Georgetown University Medical Center. Symptoms of Parkinson’s, such as motor dysfunction, are a result of a dopamine loss. In the journal Pharmacology Research & Perspectives, investigators report that a single low dose of the leukemia drug, nilotinib (Tasigna® by Novartis), reduces levels of a toxic protein that prevents the brain from utilizing dopamine that is stored…

Read More

Top News
Continence Confidence: Prostatectomy Patients Reporting ‘Startling’ Success After Robotic Retzius-Sparing Surgery
News
Continence Confidence: Prostatectomy Patients Reporting ‘Startling’ Success After Robotic…
Close
What can we
Help you Find?

Begin your search for a physician, service or location.

Find a Doctor

Start looking for the right physician to meet your health needs.

Find a Doctor

Important Parking Information

Parking for patients and visitors has changed! Click here for details.

Parking Info

Contact Us

For access to unsurpassed health care treatment, contact us now.

Contact Us